Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Novo Nordisk’s Buyback Buffer Against a Perfect Storm
Novo Nordisk launches a massive share buyback as it faces its first revenue decline in 25 years, intense…